Intrabronchial activated protein C enhances lipopolysaccharide-induced pulmonary responses
Liesbeth M Kager, J Daan de Boer, Paul Bresser, Jaring S van der Zee, Sacha Zeerleder, Joost C M Meijers, Cornelis van 't Veer, Tom van der Poll, Liesbeth M Kager, J Daan de Boer, Paul Bresser, Jaring S van der Zee, Sacha Zeerleder, Joost C M Meijers, Cornelis van 't Veer, Tom van der Poll
Abstract
Intravenous administration of activated protein C (APC) inhibits coagulation and inflammation in the lungs of humans and animals. Investigations in rodents demonstrated that direct intrapulmonary delivery of APC also exerts anticoagulant and anti-inflammatory effects. The effect of intrabronchial administration of recombinant human (rh)APC on lipopolysaccharide (LPS)-induced haemostatic and inflammatory alterations in the bronchoalveolar space of humans was studied. Eight subjects received rhAPC via intrabronchial instillation by bronchoscope, while in a contralateral subsegment subjects received saline; all subjects were challenged bilaterally with LPS in the same lung subsegments. Four additional subjects received rhAPC (75 μg), with saline as a control in the contralateral subsegment, while they were bilaterally "challenged" with saline. After 6 h a bronchoalveolar lavage was performed and coagulation and inflammatory parameters were measured. rhAPC enhanced LPS-induced coagulation activation in the bronchoalveolar space, when compared with the control side. In addition, rhAPC amplified LPS-induced pro-inflammatory responses, as indicated by higher concentrations of cytokines and chemokines. rhAPC alone did not have procoagulant or pro-inflammatory effects. Locally administered rhAPC has unexpected procoagulant and pro-inflammatory effects in LPS-challenged lung subsegments. These data argue against a role for intrapulmonary delivery of rhAPC as a treatment strategy for lung inflammatory disorders in humans.
Trial registration: ClinicalTrials.gov NCT00943267.
Source: PubMed